The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
CorrectionsFull Access

Correction to Hurd et al.

When the article “Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial,” by Yasmin L. Hurd, Ph.D., et al. (doi: 10.1176/appi.ajp.2019.18101191) was published online on May 21, 2019 and subsequently appeared as part of the November 2019 issue, there was an error in the adverse events reported in Table S4 of the data supplement. For Test Session 2 (Day 2), there were two “tired/fatigue” reports in the placebo group and none in the 800 mg cannabidiol group; also for Test Session 2 (Day 2), it should have been noted that one person accounted for the events reported in the 400 mg group. The data supplement was replaced with these changes incorporated on June 9, 2020.